

Global Liraglutide for The Treatment of Diabetes and Obesity Market Growth 2024-2030

<https://marketpublishers.com/r/G0FFD364C5DBEN.html>

Date: November 2024

Pages: 81

Price: US\$ 3,660.00 (Single User License)

ID: G0FFD364C5DBEN

Abstracts

The report requires updating with new data and is sent in 48 hours after order is placed.

Liraglutide is a medication approved for the treatment of both type 2 diabetes mellitus and obesity. It belongs to the class of glucagon-like peptide-1 (GLP-1) receptor agonists, which can enhance glucose-dependent insulin secretion, suppress glucagon release, slow gastric emptying, and promote satiety, thereby improving glycemic control and potentially aiding in weight loss.

The global Liraglutide for The Treatment of Diabetes and Obesity market size is projected to grow from US\$ million in 2024 to US\$ million in 2030; it is expected to grow at a CAGR of % from 2024 to 2030.

LP Information, Inc. (LPI) ' newest research report, the "Liraglutide for The Treatment of Diabetes and Obesity Industry Forecast" looks at past sales and reviews total world Liraglutide for The Treatment of Diabetes and Obesity sales in 2023, providing a comprehensive analysis by region and market sector of projected Liraglutide for The Treatment of Diabetes and Obesity sales for 2024 through 2030. With Liraglutide for The Treatment of Diabetes and Obesity sales broken down by region, market sector and sub-sector, this report provides a detailed analysis in US\$ millions of the world Liraglutide for The Treatment of Diabetes and Obesity industry.

This Insight Report provides a comprehensive analysis of the global Liraglutide for The Treatment of Diabetes and Obesity landscape and highlights key trends related to product segmentation, company formation, revenue, and market share, latest development, and M&A activity. This report also analyzes the strategies of leading global companies with a focus on Liraglutide for The Treatment of Diabetes and Obesity

portfolios and capabilities, market entry strategies, market positions, and geographic footprints, to better understand these firms' unique position in an accelerating global Liraglutide for The Treatment of Diabetes and Obesity market.

This Insight Report evaluates the key market trends, drivers, and affecting factors shaping the global outlook for Liraglutide for The Treatment of Diabetes and Obesity and breaks down the forecast by Type, by Application, geography, and market size to highlight emerging pockets of opportunity. With a transparent methodology based on hundreds of bottom-up qualitative and quantitative market inputs, this study forecast offers a highly nuanced view of the current state and future trajectory in the global Liraglutide for The Treatment of Diabetes and Obesity.

United States market for Liraglutide for The Treatment of Diabetes and Obesity is estimated to increase from US\$ million in 2023 to US\$ million by 2030, at a CAGR of % from 2024 through 2030.

China market for Liraglutide for The Treatment of Diabetes and Obesity is estimated to increase from US\$ million in 2023 to US\$ million by 2030, at a CAGR of % from 2024 through 2030.

Europe market for Liraglutide for The Treatment of Diabetes and Obesity is estimated to increase from US\$ million in 2023 to US\$ million by 2030, at a CAGR of % from 2024 through 2030.

Global key Liraglutide for The Treatment of Diabetes and Obesity players cover Novo Nordisk, Teva, Huadong Medicine, Sino Biopharm, etc. In terms of revenue, the global two largest companies occupied for a share nearly

% in 2023.

This report presents a comprehensive overview, market shares, and growth opportunities of Liraglutide for The Treatment of Diabetes and Obesity market by product type, application, key manufacturers and key regions and countries.

Segmentation by Type:

Original Drug

Generic Drug

Segmentation by Application:

Hospital and Clinic

Retail Pharmacies

Other

This report also splits the market by region:

Americas

United States

Canada

Mexico

Brazil

APAC

China

Japan

Korea

Southeast Asia

India

Australia

Europe

Germany

France

UK

Italy

Russia

Middle East & Africa

Egypt

South Africa

Israel

Turkey

GCC Countries

The below companies that are profiled have been selected based on inputs gathered from primary experts and analysing the company's coverage, product portfolio, its market penetration.

Novo Nordisk

Teva

Huadong Medicine

Sino Biopharm

Key Questions Addressed in this Report

What is the 10-year outlook for the global Liraglutide for The Treatment of Diabetes and

Obesity market?

What factors are driving Liraglutide for The Treatment of Diabetes and Obesity market growth, globally and by region?

Which technologies are poised for the fastest growth by market and region?

How do Liraglutide for The Treatment of Diabetes and Obesity market opportunities vary by end market size?

How does Liraglutide for The Treatment of Diabetes and Obesity break out by Type, by Application?

Contents

1 SCOPE OF THE REPORT

- 1.1 Market Introduction
- 1.2 Years Considered
- 1.3 Research Objectives
- 1.4 Market Research Methodology
- 1.5 Research Process and Data Source
- 1.6 Economic Indicators
- 1.7 Currency Considered
- 1.8 Market Estimation Caveats

2 EXECUTIVE SUMMARY

2.1 World Market Overview

- 2.1.1 Global Liraglutide for The Treatment of Diabetes and Obesity Annual Sales 2019-2030

- 2.1.2 World Current & Future Analysis for Liraglutide for The Treatment of Diabetes and Obesity by Geographic Region, 2019, 2023 & 2030

- 2.1.3 World Current & Future Analysis for Liraglutide for The Treatment of Diabetes and Obesity by Country/Region, 2019, 2023 & 2030

2.2 Liraglutide for The Treatment of Diabetes and Obesity Segment by Type

- 2.2.1 Original Drug

- 2.2.2 Generic Drug

2.3 Liraglutide for The Treatment of Diabetes and Obesity Sales by Type

- 2.3.1 Global Liraglutide for The Treatment of Diabetes and Obesity Sales Market Share by Type (2019-2024)

- 2.3.2 Global Liraglutide for The Treatment of Diabetes and Obesity Revenue and Market Share by Type (2019-2024)

- 2.3.3 Global Liraglutide for The Treatment of Diabetes and Obesity Sale Price by Type (2019-2024)

2.4 Liraglutide for The Treatment of Diabetes and Obesity Segment by Application

- 2.4.1 Hospital and Clinic

- 2.4.2 Retail Pharmacies

- 2.4.3 Other

2.5 Liraglutide for The Treatment of Diabetes and Obesity Sales by Application

- 2.5.1 Global Liraglutide for The Treatment of Diabetes and Obesity Sale Market Share by Application (2019-2024)

2.5.2 Global Liraglutide for The Treatment of Diabetes and Obesity Revenue and Market Share by Application (2019-2024)

2.5.3 Global Liraglutide for The Treatment of Diabetes and Obesity Sale Price by Application (2019-2024)

3 GLOBAL BY COMPANY

3.1 Global Liraglutide for The Treatment of Diabetes and Obesity Breakdown Data by Company

3.1.1 Global Liraglutide for The Treatment of Diabetes and Obesity Annual Sales by Company (2019-2024)

3.1.2 Global Liraglutide for The Treatment of Diabetes and Obesity Sales Market Share by Company (2019-2024)

3.2 Global Liraglutide for The Treatment of Diabetes and Obesity Annual Revenue by Company (2019-2024)

3.2.1 Global Liraglutide for The Treatment of Diabetes and Obesity Revenue by Company (2019-2024)

3.2.2 Global Liraglutide for The Treatment of Diabetes and Obesity Revenue Market Share by Company (2019-2024)

3.3 Global Liraglutide for The Treatment of Diabetes and Obesity Sale Price by Company

3.4 Key Manufacturers Liraglutide for The Treatment of Diabetes and Obesity Producing Area Distribution, Sales Area, Product Type

3.4.1 Key Manufacturers Liraglutide for The Treatment of Diabetes and Obesity Product Location Distribution

3.4.2 Players Liraglutide for The Treatment of Diabetes and Obesity Products Offered

3.5 Market Concentration Rate Analysis

3.5.1 Competition Landscape Analysis

3.5.2 Concentration Ratio (CR3, CR5 and CR10) & (2019-2024)

3.6 New Products and Potential Entrants

3.7 Market M&A Activity & Strategy

4 WORLD HISTORIC REVIEW FOR LIRAGLUTIDE FOR THE TREATMENT OF DIABETES AND OBESITY BY GEOGRAPHIC REGION

4.1 World Historic Liraglutide for The Treatment of Diabetes and Obesity Market Size by Geographic Region (2019-2024)

4.1.1 Global Liraglutide for The Treatment of Diabetes and Obesity Annual Sales by Geographic Region (2019-2024)

- 4.1.2 Global Liraglutide for The Treatment of Diabetes and Obesity Annual Revenue by Geographic Region (2019-2024)
- 4.2 World Historic Liraglutide for The Treatment of Diabetes and Obesity Market Size by Country/Region (2019-2024)
 - 4.2.1 Global Liraglutide for The Treatment of Diabetes and Obesity Annual Sales by Country/Region (2019-2024)
 - 4.2.2 Global Liraglutide for The Treatment of Diabetes and Obesity Annual Revenue by Country/Region (2019-2024)
- 4.3 Americas Liraglutide for The Treatment of Diabetes and Obesity Sales Growth
- 4.4 APAC Liraglutide for The Treatment of Diabetes and Obesity Sales Growth
- 4.5 Europe Liraglutide for The Treatment of Diabetes and Obesity Sales Growth
- 4.6 Middle East & Africa Liraglutide for The Treatment of Diabetes and Obesity Sales Growth

5 AMERICAS

- 5.1 Americas Liraglutide for The Treatment of Diabetes and Obesity Sales by Country
 - 5.1.1 Americas Liraglutide for The Treatment of Diabetes and Obesity Sales by Country (2019-2024)
 - 5.1.2 Americas Liraglutide for The Treatment of Diabetes and Obesity Revenue by Country (2019-2024)
- 5.2 Americas Liraglutide for The Treatment of Diabetes and Obesity Sales by Type (2019-2024)
- 5.3 Americas Liraglutide for The Treatment of Diabetes and Obesity Sales by Application (2019-2024)
- 5.4 United States
- 5.5 Canada
- 5.6 Mexico
- 5.7 Brazil

6 APAC

- 6.1 APAC Liraglutide for The Treatment of Diabetes and Obesity Sales by Region
 - 6.1.1 APAC Liraglutide for The Treatment of Diabetes and Obesity Sales by Region (2019-2024)
 - 6.1.2 APAC Liraglutide for The Treatment of Diabetes and Obesity Revenue by Region (2019-2024)
- 6.2 APAC Liraglutide for The Treatment of Diabetes and Obesity Sales by Type (2019-2024)

6.3 APAC Liraglutide for The Treatment of Diabetes and Obesity Sales by Application (2019-2024)

6.4 China

6.5 Japan

6.6 South Korea

6.7 Southeast Asia

6.8 India

6.9 Australia

6.10 China Taiwan

7 EUROPE

7.1 Europe Liraglutide for The Treatment of Diabetes and Obesity by Country

7.1.1 Europe Liraglutide for The Treatment of Diabetes and Obesity Sales by Country (2019-2024)

7.1.2 Europe Liraglutide for The Treatment of Diabetes and Obesity Revenue by Country (2019-2024)

7.2 Europe Liraglutide for The Treatment of Diabetes and Obesity Sales by Type (2019-2024)

7.3 Europe Liraglutide for The Treatment of Diabetes and Obesity Sales by Application (2019-2024)

7.4 Germany

7.5 France

7.6 UK

7.7 Italy

7.8 Russia

8 MIDDLE EAST & AFRICA

8.1 Middle East & Africa Liraglutide for The Treatment of Diabetes and Obesity by Country

8.1.1 Middle East & Africa Liraglutide for The Treatment of Diabetes and Obesity Sales by Country (2019-2024)

8.1.2 Middle East & Africa Liraglutide for The Treatment of Diabetes and Obesity Revenue by Country (2019-2024)

8.2 Middle East & Africa Liraglutide for The Treatment of Diabetes and Obesity Sales by Type (2019-2024)

8.3 Middle East & Africa Liraglutide for The Treatment of Diabetes and Obesity Sales by Application (2019-2024)

- 8.4 Egypt
- 8.5 South Africa
- 8.6 Israel
- 8.7 Turkey
- 8.8 GCC Countries

9 MARKET DRIVERS, CHALLENGES AND TRENDS

- 9.1 Market Drivers & Growth Opportunities
- 9.2 Market Challenges & Risks
- 9.3 Industry Trends

10 MANUFACTURING COST STRUCTURE ANALYSIS

- 10.1 Raw Material and Suppliers
- 10.2 Manufacturing Cost Structure Analysis of Liraglutide for The Treatment of Diabetes and Obesity
- 10.3 Manufacturing Process Analysis of Liraglutide for The Treatment of Diabetes and Obesity
- 10.4 Industry Chain Structure of Liraglutide for The Treatment of Diabetes and Obesity

11 MARKETING, DISTRIBUTORS AND CUSTOMER

- 11.1 Sales Channel
 - 11.1.1 Direct Channels
 - 11.1.2 Indirect Channels
- 11.2 Liraglutide for The Treatment of Diabetes and Obesity Distributors
- 11.3 Liraglutide for The Treatment of Diabetes and Obesity Customer

12 WORLD FORECAST REVIEW FOR LIRAGLUTIDE FOR THE TREATMENT OF DIABETES AND OBESITY BY GEOGRAPHIC REGION

- 12.1 Global Liraglutide for The Treatment of Diabetes and Obesity Market Size Forecast by Region
 - 12.1.1 Global Liraglutide for The Treatment of Diabetes and Obesity Forecast by Region (2025-2030)
 - 12.1.2 Global Liraglutide for The Treatment of Diabetes and Obesity Annual Revenue Forecast by Region (2025-2030)
- 12.2 Americas Forecast by Country (2025-2030)

- 12.3 APAC Forecast by Region (2025-2030)
- 12.4 Europe Forecast by Country (2025-2030)
- 12.5 Middle East & Africa Forecast by Country (2025-2030)
- 12.6 Global Liraglutide for The Treatment of Diabetes and Obesity Forecast by Type (2025-2030)
- 12.7 Global Liraglutide for The Treatment of Diabetes and Obesity Forecast by Application (2025-2030)

13 KEY PLAYERS ANALYSIS

13.1 Novo Nordisk

13.1.1 Novo Nordisk Company Information

13.1.2 Novo Nordisk Liraglutide for The Treatment of Diabetes and Obesity Product Portfolios and Specifications

13.1.3 Novo Nordisk Liraglutide for The Treatment of Diabetes and Obesity Sales, Revenue, Price and Gross Margin (2019-2024)

13.1.4 Novo Nordisk Main Business Overview

13.1.5 Novo Nordisk Latest Developments

13.2 Teva

13.2.1 Teva Company Information

13.2.2 Teva Liraglutide for The Treatment of Diabetes and Obesity Product Portfolios and Specifications

13.2.3 Teva Liraglutide for The Treatment of Diabetes and Obesity Sales, Revenue, Price and Gross Margin (2019-2024)

13.2.4 Teva Main Business Overview

13.2.5 Teva Latest Developments

13.3 Huadong Medicine

13.3.1 Huadong Medicine Company Information

13.3.2 Huadong Medicine Liraglutide for The Treatment of Diabetes and Obesity Product Portfolios and Specifications

13.3.3 Huadong Medicine Liraglutide for The Treatment of Diabetes and Obesity Sales, Revenue, Price and Gross Margin (2019-2024)

13.3.4 Huadong Medicine Main Business Overview

13.3.5 Huadong Medicine Latest Developments

13.4 Sino Biopharm

13.4.1 Sino Biopharm Company Information

13.4.2 Sino Biopharm Liraglutide for The Treatment of Diabetes and Obesity Product Portfolios and Specifications

13.4.3 Sino Biopharm Liraglutide for The Treatment of Diabetes and Obesity Sales,

Revenue, Price and Gross Margin (2019-2024)

13.4.4 Sino Biopharm Main Business Overview

13.4.5 Sino Biopharm Latest Developments

14 RESEARCH FINDINGS AND CONCLUSION

LIST OF TABLES

Table 1. Liraglutide for The Treatment of Diabetes and Obesity Annual Sales CAGR by Geographic Region (2019, 2023 & 2030) & (\$ millions)

Table 2. Liraglutide for The Treatment of Diabetes and Obesity Annual Sales CAGR by Country/Region (2019, 2023 & 2030) & (\$ millions)

Table 3. Major Players of Original Drug

Table 4. Major Players of Generic Drug

Table 5. Global Liraglutide for The Treatment of Diabetes and Obesity Sales by Type (2019-2024) & (K Dose)

Table 6. Global Liraglutide for The Treatment of Diabetes and Obesity Sales Market Share by Type (2019-2024)

Table 7. Global Liraglutide for The Treatment of Diabetes and Obesity Revenue by Type (2019-2024) & (\$ million)

Table 8. Global Liraglutide for The Treatment of Diabetes and Obesity Revenue Market Share by Type (2019-2024)

Table 9. Global Liraglutide for The Treatment of Diabetes and Obesity Sale Price by Type (2019-2024) & (US\$/Dose)

Table 10. Global Liraglutide for The Treatment of Diabetes and Obesity Sale by Application (2019-2024) & (K Dose)

Table 11. Global Liraglutide for The Treatment of Diabetes and Obesity Sale Market Share by Application (2019-2024)

Table 12. Global Liraglutide for The Treatment of Diabetes and Obesity Revenue by Application (2019-2024) & (\$ million)

Table 13. Global Liraglutide for The Treatment of Diabetes and Obesity Revenue Market Share by Application (2019-2024)

Table 14. Global Liraglutide for The Treatment of Diabetes and Obesity Sale Price by Application (2019-2024) & (US\$/Dose)

Table 15. Global Liraglutide for The Treatment of Diabetes and Obesity Sales by Company (2019-2024) & (K Dose)

Table 16. Global Liraglutide for The Treatment of Diabetes and Obesity Sales Market Share by Company (2019-2024)

Table 17. Global Liraglutide forTheTreatment of Diabetes and Obesity Revenue by Company (2019-2024) & (\$ millions)

Table 18. Global Liraglutide forTheTreatment of Diabetes and Obesity Revenue Market Share by Company (2019-2024)

Table 19. Global Liraglutide forTheTreatment of Diabetes and Obesity Sale Price by Company (2019-2024) & (US\$/Dose)

Table 20. Key Manufacturers Liraglutide forTheTreatment of Diabetes and Obesity Producing Area Distribution and Sales Area

Table 21. Players Liraglutide forTheTreatment of Diabetes and Obesity Products Offered

Table 22. Liraglutide forTheTreatment of Diabetes and Obesity Concentration Ratio (CR3, CR5 and CR10) & (2019-2024)

Table 23. New Products and Potential Entrants

Table 24. Market M&A Activity & Strategy

Table 25. Global Liraglutide forTheTreatment of Diabetes and Obesity Sales by Geographic Region (2019-2024) & (K Dose)

Table 26. Global Liraglutide forTheTreatment of Diabetes and Obesity Sales Market Share Geographic Region (2019-2024)

Table 27. Global Liraglutide forTheTreatment of Diabetes and Obesity Revenue by Geographic Region (2019-2024) & (\$ millions)

Table 28. Global Liraglutide forTheTreatment of Diabetes and Obesity Revenue Market Share by Geographic Region (2019-2024)

Table 29. Global Liraglutide forTheTreatment of Diabetes and Obesity Sales by Country/Region (2019-2024) & (K Dose)

Table 30. Global Liraglutide forTheTreatment of Diabetes and Obesity Sales Market Share by Country/Region (2019-2024)

Table 31. Global Liraglutide forTheTreatment of Diabetes and Obesity Revenue by Country/Region (2019-2024) & (\$ millions)

Table 32. Global Liraglutide forTheTreatment of Diabetes and Obesity Revenue Market Share by Country/Region (2019-2024)

Table 33. Americas Liraglutide forTheTreatment of Diabetes and Obesity Sales by Country (2019-2024) & (K Dose)

Table 34. Americas Liraglutide forTheTreatment of Diabetes and Obesity Sales Market Share by Country (2019-2024)

Table 35. Americas Liraglutide forTheTreatment of Diabetes and Obesity Revenue by Country (2019-2024) & (\$ millions)

Table 36. Americas Liraglutide forTheTreatment of Diabetes and Obesity Sales byType (2019-2024) & (K Dose)

Table 37. Americas Liraglutide forTheTreatment of Diabetes and Obesity Sales by

Application (2019-2024) & (K Dose)

Table 38. APAC Liraglutide forTheTreatment of Diabetes and Obesity Sales by Region (2019-2024) & (K Dose)

Table 39. APAC Liraglutide forTheTreatment of Diabetes and Obesity Sales Market Share by Region (2019-2024)

Table 40. APAC Liraglutide forTheTreatment of Diabetes and Obesity Revenue by Region (2019-2024) & (\$ millions)

Table 41. APAC Liraglutide forTheTreatment of Diabetes and Obesity Sales byType (2019-2024) & (K Dose)

Table 42. APAC Liraglutide forTheTreatment of Diabetes and Obesity Sales by Application (2019-2024) & (K Dose)

Table 43. Europe Liraglutide forTheTreatment of Diabetes and Obesity Sales by Country (2019-2024) & (K Dose)

Table 44. Europe Liraglutide forTheTreatment of Diabetes and Obesity Revenue by Country (2019-2024) & (\$ millions)

Table 45. Europe Liraglutide forTheTreatment of Diabetes and Obesity Sales byType (2019-2024) & (K Dose)

Table 46. Europe Liraglutide forTheTreatment of Diabetes and Obesity Sales by Application (2019-2024) & (K Dose)

Table 47. Middle East & Africa Liraglutide forTheTreatment of Diabetes and Obesity Sales by Country (2019-2024) & (K Dose)

Table 48. Middle East & Africa Liraglutide forTheTreatment of Diabetes and Obesity Revenue Market Share by Country (2019-2024)

Table 49. Middle East & Africa Liraglutide forTheTreatment of Diabetes and Obesity Sales byType (2019-2024) & (K Dose)

Table 50. Middle East & Africa Liraglutide forTheTreatment of Diabetes and Obesity Sales by Application (2019-2024) & (K Dose)

Table 51. Key Market Drivers & Growth Opportunities of Liraglutide forTheTreatment of Diabetes and Obesity

Table 52. Key Market Challenges & Risks of Liraglutide forTheTreatment of Diabetes and Obesity

Table 53. Key IndustryTrends of Liraglutide forTheTreatment of Diabetes and Obesity

Table 54. Liraglutide forTheTreatment of Diabetes and Obesity Raw Material

Table 55. Key Suppliers of Raw Materials

Table 56. Liraglutide forTheTreatment of Diabetes and Obesity Distributors List

Table 57. Liraglutide forTheTreatment of Diabetes and Obesity Customer List

Table 58. Global Liraglutide forTheTreatment of Diabetes and Obesity SalesForecast by Region (2025-2030) & (K Dose)

Table 59. Global Liraglutide forTheTreatment of Diabetes and Obesity

Revenue Forecast by Region (2025-2030) & (\$ millions)

Table 60. Americas Liraglutide for The Treatment of Diabetes and Obesity Sales Forecast by Country (2025-2030) & (K Dose)

Table 61. Americas Liraglutide for The Treatment of Diabetes and Obesity Annual Revenue Forecast by Country (2025-2030) & (\$ millions)

Table 62. APAC Liraglutide for The Treatment of Diabetes and Obesity Sales Forecast by Region (2025-2030) & (K Dose)

Table 63. APAC Liraglutide for The Treatment of Diabetes and Obesity Annual Revenue Forecast by Region (2025-2030) & (\$ millions)

Table 64. Europe Liraglutide for The Treatment of Diabetes and Obesity Sales Forecast by Country (2025-2030) & (K Dose)

Table 65. Europe Liraglutide for The Treatment of Diabetes and Obesity Revenue Forecast by Country (2025-2030) & (\$ millions)

Table 66. Middle East & Africa Liraglutide for The Treatment of Diabetes and Obesity Sales Forecast by Country (2025-2030) & (K Dose)

Table 67. Middle East & Africa Liraglutide for The Treatment of Diabetes and Obesity Revenue Forecast by Country (2025-2030) & (\$ millions)

Table 68. Global Liraglutide for The Treatment of Diabetes and Obesity Sales Forecast by Type (2025-2030) & (K Dose)

Table 69. Global Liraglutide for The Treatment of Diabetes and Obesity Revenue Forecast by Type (2025-2030) & (\$ millions)

Table 70. Global Liraglutide for The Treatment of Diabetes and Obesity Sales Forecast by Application (2025-2030) & (K Dose)

Table 71. Global Liraglutide for The Treatment of Diabetes and Obesity Revenue Forecast by Application (2025-2030) & (\$ millions)

Table 72. Novo Nordisk Basic Information, Liraglutide for The Treatment of Diabetes and Obesity Manufacturing Base, Sales Area and Its Competitors

Table 73. Novo Nordisk Liraglutide for The Treatment of Diabetes and Obesity Product Portfolios and Specifications

Table 74. Novo Nordisk Liraglutide for The Treatment of Diabetes and Obesity Sales (K Dose), Revenue (\$ Million), Price (US\$/Dose) and Gross Margin (2019-2024)

Table 75. Novo Nordisk Main Business

Table 76. Novo Nordisk Latest Developments

Table 77. Teva Basic Information, Liraglutide for The Treatment of Diabetes and Obesity Manufacturing Base, Sales Area and Its Competitors

Table 78. Teva Liraglutide for The Treatment of Diabetes and Obesity Product Portfolios and Specifications

Table 79. Teva Liraglutide for The Treatment of Diabetes and Obesity Sales (K Dose), Revenue (\$ Million), Price (US\$/Dose) and Gross Margin (2019-2024)

Table 80. Teva Main Business

Table 81. Teva Latest Developments

Table 82. Huadong Medicine Basic Information, Liraglutide for The Treatment of Diabetes and Obesity Manufacturing Base, Sales Area and Its Competitors

Table 83. Huadong Medicine Liraglutide for The Treatment of Diabetes and Obesity Product Portfolios and Specifications

Table 84. Huadong Medicine Liraglutide for The Treatment of Diabetes and Obesity Sales (K Dose), Revenue (\$ Million), Price (US\$/Dose) and Gross Margin (2019-2024)

Table 85. Huadong Medicine Main Business

Table 86. Huadong Medicine Latest Developments

Table 87. Sino Biopharm Basic Information, Liraglutide for The Treatment of Diabetes and Obesity Manufacturing Base, Sales Area and Its Competitors

Table 88. Sino Biopharm Liraglutide for The Treatment of Diabetes and Obesity Product Portfolios and Specifications

Table 89. Sino Biopharm Liraglutide for The Treatment of Diabetes and Obesity Sales (K Dose), Revenue (\$ Million), Price (US\$/Dose) and Gross Margin (2019-2024)

Table 90. Sino Biopharm Main Business

Table 91. Sino Biopharm Latest Developments

LIST OFFIGURES

Figure 1. Picture of Liraglutide for The Treatment of Diabetes and Obesity

Figure 2. Liraglutide for The Treatment of Diabetes and Obesity Report Years Considered

Figure 3. Research Objectives

Figure 4. Research Methodology

Figure 5. Research Process and Data Source

Figure 6. Global Liraglutide for The Treatment of Diabetes and Obesity Sales Growth Rate 2019-2030 (K Dose)

Figure 7. Global Liraglutide for The Treatment of Diabetes and Obesity Revenue Growth Rate 2019-2030 (\$ millions)

Figure 8. Liraglutide for The Treatment of Diabetes and Obesity Sales by Geographic Region (2019, 2023 & 2030) & (\$ millions)

Figure 9. Liraglutide for The Treatment of Diabetes and Obesity Sales Market Share by Country/Region (2023)

Figure 10. Liraglutide for The Treatment of Diabetes and Obesity Sales Market Share by Country/Region (2019, 2023 & 2030)

Figure 11. Product Picture of Original Drug

Figure 12. Product Picture of Generic Drug

Figure 13. Global Liraglutide forTheTreatment of Diabetes and Obesity Sales Market Share byType in 2023

Figure 14. Global Liraglutide forTheTreatment of Diabetes and Obesity Revenue Market Share byType (2019-2024)

Figure 15. Liraglutide forTheTreatment of Diabetes and Obesity Consumed in Hospital and Clinic

Figure 16. Global Liraglutide forTheTreatment of Diabetes and Obesity Market: Hospital and Clinic (2019-2024) & (K Dose)

Figure 17. Liraglutide forTheTreatment of Diabetes and Obesity Consumed in Retail Pharmacies

Figure 18. Global Liraglutide forTheTreatment of Diabetes and Obesity Market: Retail Pharmacies (2019-2024) & (K Dose)

Figure 19. Liraglutide forTheTreatment of Diabetes and Obesity Consumed in Other

Figure 20. Global Liraglutide forTheTreatment of Diabetes and Obesity Market: Other (2019-2024) & (K Dose)

Figure 21. Global Liraglutide forTheTreatment of Diabetes and Obesity Sale Market Share by Application (2023)

Figure 22. Global Liraglutide forTheTreatment of Diabetes and Obesity Revenue Market Share by Application in 2023

Figure 23. Liraglutide forTheTreatment of Diabetes and Obesity Sales by Company in 2023 (K Dose)

Figure 24. Global Liraglutide forTheTreatment of Diabetes and Obesity Sales Market Share by Company in 2023

Figure 25. Liraglutide forTheTreatment of Diabetes and Obesity Revenue by Company in 2023 (\$ millions)

Figure 26. Global Liraglutide forTheTreatment of Diabetes and Obesity Revenue Market Share by Company in 2023

Figure 27. Global Liraglutide forTheTreatment of Diabetes and Obesity Sales Market Share by Geographic Region (2019-2024)

Figure 28. Global Liraglutide forTheTreatment of Diabetes and Obesity Revenue Market Share by Geographic Region in 2023

Figure 29. Americas Liraglutide forTheTreatment of Diabetes and Obesity Sales 2019-2024 (K Dose)

Figure 30. Americas Liraglutide forTheTreatment of Diabetes and Obesity Revenue 2019-2024 (\$ millions)

Figure 31. APAC Liraglutide forTheTreatment of Diabetes and Obesity Sales 2019-2024 (K Dose)

Figure 32. APAC Liraglutide forTheTreatment of Diabetes and Obesity Revenue 2019-2024 (\$ millions)

Figure 33. Europe Liraglutide forTheTreatment of Diabetes and Obesity Sales 2019-2024 (K Dose)

Figure 34. Europe Liraglutide forTheTreatment of Diabetes and Obesity Revenue 2019-2024 (\$ millions)

Figure 35. Middle East & Africa Liraglutide forTheTreatment of Diabetes and Obesity Sales 2019-2024 (K Dose)

Figure 36. Middle East & Africa Liraglutide forTheTreatment of Diabetes and Obesity Revenue 2019-2024 (\$ millions)

Figure 37. Americas Liraglutide forTheTreatment of Diabetes and Obesity Sales Market Share by Country in 2023

Figure 38. Americas Liraglutide forTheTreatment of Diabetes and Obesity Revenue Market Share by Country (2019-2024)

Figure 39. Americas Liraglutide forTheTreatment of Diabetes and Obesity Sales Market Share byType (2019-2024)

Figure 40. Americas Liraglutide forTheTreatment of Diabetes and Obesity Sales Market Share by Application (2019-2024)

Figure 41. United States Liraglutide forTheTreatment of Diabetes and Obesity Revenue Growth 2019-2024 (\$ millions)

Figure 42. Canada Liraglutide forTheTreatment of Diabetes and Obesity Revenue Growth 2019-2024 (\$ millions)

Figure 43. Mexico Liraglutide forTheTreatment of Diabetes and Obesity Revenue Growth 2019-2024 (\$ millions)

Figure 44. Brazil Liraglutide forTheTreatment of Diabetes and Obesity Revenue Growth 2019-2024 (\$ millions)

Figure 45. APAC Liraglutide forTheTreatment of Diabetes and Obesity Sales Market Share by Region in 2023

Figure 46. APAC Liraglutide forTheTreatment of Diabetes and Obesity Revenue Market Share by Region (2019-2024)

Figure 47. APAC Liraglutide forTheTreatment of Diabetes and Obesity Sales Market Share byType (2019-2024)

Figure 48. APAC Liraglutide forTheTreatment of Diabetes and Obesity Sales Market Share by Application (2019-2024)

Figure 49. China Liraglutide forTheTreatment of Diabetes and Obesity Revenue Growth 2019-2024 (\$ millions)

Figure 50. Japan Liraglutide forTheTreatment of Diabetes and Obesity Revenue Growth 2019-2024 (\$ millions)

Figure 51. South Korea Liraglutide forTheTreatment of Diabetes and Obesity Revenue

Growth 2019-2024 (\$ millions)

Figure 52. Southeast Asia Liraglutide for The Treatment of Diabetes and Obesity

Revenue Growth 2019-2024 (\$ millions)

Figure 53. India Liraglutide for The Treatment of Diabetes and Obesity Revenue Growth

2019-2024 (\$ millions)

Figure 54. Australia Liraglutide for The Treatment of Diabetes and Obesity Revenue

Growth 2019-2024 (\$ millions)

Figure 55. China Taiwan Liraglutide for The Treatment of Diabetes and Obesity Revenue

Growth 2019-2024 (\$ millions)

Figure 56. Europe Liraglutide for The Treatment of Diabetes and Obesity Sales Market

Share by Country in 2023

Figure 57. Europe Liraglutide for The Treatment of Diabetes and Obesity Revenue

Market Share by Country (2019-2024)

Figure 58. Europe Liraglutide for The Treatment of Diabetes and Obesity Sales Market

Share by Type (2019-2024)

Figure 59. Europe Liraglutide for The Treatment of Diabetes and Obesity Sales Market

Share by Application (2019-2024)

Figure 60. Germany Liraglutide for The Treatment of Diabetes and Obesity Revenue

Growth 2019-2024 (\$ millions)

Figure 61. France Liraglutide for The Treatment of Diabetes and Obesity Revenue Growth

2019-2024 (\$ millions)

Figure 62. UK Liraglutide for The Treatment of Diabetes and Obesity Revenue Growth

2019-2024 (\$ millions)

Figure 63. Italy Liraglutide for The Treatment of Diabetes and Obesity Revenue Growth

2019-2024 (\$ millions)

Figure 64. Russia Liraglutide for The Treatment of Diabetes and Obesity Revenue

Growth 2019-2024 (\$ millions)

Figure 65. Middle East & Africa Liraglutide for The Treatment of Diabetes and Obesity

Sales Market Share by Country (2019-2024)

Figure 66. Middle East & Africa Liraglutide for The Treatment of Diabetes and Obesity

Sales Market Share by Type (2019-2024)

Figure 67. Middle East & Africa Liraglutide for The Treatment of Diabetes and Obesity

Sales Market Share by Application (2019-2024)

Figure 68. Egypt Liraglutide for The Treatment of Diabetes and Obesity Revenue Growth

2019-2024 (\$ millions)

Figure 69. South Africa Liraglutide for The Treatment of Diabetes and Obesity Revenue

Growth 2019-2024 (\$ millions)

Figure 70. Israel Liraglutide for The Treatment of Diabetes and Obesity Revenue Growth

2019-2024 (\$ millions)

Figure 71. Turkey Liraglutide for The Treatment of Diabetes and Obesity Revenue Growth 2019-2024 (\$ millions)

Figure 72. GCC Countries Liraglutide for The Treatment of Diabetes and Obesity Revenue Growth 2019-2024 (\$ millions)

Figure 73. Manufacturing Cost Structure Analysis of Liraglutide for The Treatment of Diabetes and Obesity in 2023

Figure 74. Manufacturing Process Analysis of Liraglutide for The Treatment of Diabetes and Obesity

Figure 75. Industry Chain Structure of Liraglutide for The Treatment of Diabetes and Obesity

Figure 76. Channels of Distribution

Figure 77. Global Liraglutide for The Treatment of Diabetes and Obesity Sales Market Forecast by Region (2025-2030)

Figure 78. Global Liraglutide for The Treatment of Diabetes and Obesity Revenue Market Share Forecast by Region (2025-2030)

Figure 79. Global Liraglutide for The Treatment of Diabetes and Obesity Sales Market Share Forecast by Type (2025-2030)

Figure 80. Global Liraglutide for The Treatment of Diabetes and Obesity Revenue Market Share Forecast by Type (2025-2030)

Figure 81. Global Liraglutide for The Treatment of Diabetes and Obesity Sales Market Share Forecast by Application (2025-2030)

Figure 82. Global Liraglutide for The Treatment of Diabetes and Obesity Revenue Market Share Forecast by Application (2025-2030)

I would like to order

Product name: Global Liraglutide for The Treatment of Diabetes and Obesity Market Growth 2024-2030

Product link: <https://marketpublishers.com/r/G0FFD364C5DBEN.html>

Price: US\$ 3,660.00 (Single User License / Electronic Delivery)

If you want to order Corporate License or Hard Copy, please, contact our Customer Service:

info@marketpublishers.com

Payment

To pay by Credit Card (Visa, MasterCard, American Express, PayPal), please, click button on product page <https://marketpublishers.com/r/G0FFD364C5DBEN.html>

To pay by Wire Transfer, please, fill in your contact details in the form below:

First name:
Last name:
Email:
Company:
Address:
City:
Zip code:
Country:
Tel:
Fax:
Your message:

****All fields are required**

Customer signature _____

Please, note that by ordering from marketpublishers.com you are agreeing to our Terms & Conditions at <https://marketpublishers.com/docs/terms.html>

To place an order via fax simply print this form, fill in the information below and fax the completed form to +44 20 7900 3970